Investors looking for stocks in the Medical - Drugs sector might want to consider either Grifols (GRFS) or Stevanato Group (STVN). But which of these two stocks offers value investors a better bang ...

Health Minister Khaled Abdel Ghaffar met on Sunday, June 1st, 2025, with Magdy Amin, Chairman of Grifols Egypt, to discuss expanding cooperation in haematology and the national plasma derivatives ...

This summary of recent health news covers a U.S. government report error, China's ban on Brazilian poultry, legal action by ...

Grifols (GRFS) secures a win in its defamation lawsuit against Gotham City Research in the U.S. Read more here.

MADRID (Reuters) -A New York court has found enough evidence to proceed with a defamation lawsuit filed by Grifols against ...

A New York court found enough evidence to continue with the defamation lawsuit filed by Spanish pharmaceutical company ...

At current levels, GRFS scores over ADMA with cheaper valuation, a broad portfolio, and strong EPS growth estimates despite the latter's robust Asceniv-driven momentum.

The FDA cleared an investigational new drug application for a phase 2 trial of GRF312 ophthalmic solution, an immunoglobulin ...

Grifols offers compelling long-term upside, with potential returns exceeding 200% as the company recovers and grows earnings.

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

A Leeds-based creator of simulation software to train medical staff on laboratory equipment has secured £1m investment.